|
| 消风散联合复方甘草酸苷对慢性荨麻疹患者FⅫa、GATA-3的作用及疗效影响因素研究 |
|
| 投稿时间：2025-08-27 修订日期：2026-04-16 |
| DOI： |
| 中文关键词: 慢性荨麻疹 消风散 复方甘草酸苷 活化凝血因子Ⅻ GATA连接蛋白-3 疗效 影响因素 |
| 英文关键词: |
| 基金项目: |
|
| 摘要点击次数: 2 |
| 全文下载次数: 0 |
| 中文摘要: |
| 【】目的:探究慢性荨麻疹患者采用消风散联合复方甘草酸苷治疗对活化凝血因子Ⅻ(FⅫa)、GATA连接蛋白-3(GATA-3)水平的影响,并进一步探究疗效的影响因素。方法:选取2023年6月-2024年6月在我院就诊的84例慢性荨麻疹患者,依据随机数字表法分为研究组和对照组,各42例。对照组患者采用复方甘草酸苷片口服治疗,研究组患者进行消风散汤剂+复方甘草酸苷片口服治疗,两组均进行4周的治疗。比较两组治疗前后的症状评分、免疫功能(CD4+、CD8+、CD4+/CD8+)、炎症因子[白三烯(LT)、白细胞介素-4(IL-4)、扰素-γ(IFN-γ)]、FⅫa、GATA-3；统计两组患者治疗有效率,采用Logistic回归分析疗效的影响因素；观察不良反应发生率。结果:两组患者治疗后FⅫa、GATA-3表达及症状积分、CD8+明显低于治疗前(P＜0.05),CD4+、CD4+/CD8+高于治疗前(P＜0.05)；研究组治疗后FⅫa、GATA-3表达及症状积分、CD8+低于对照组(P＜0.05),CD4+、CD4+/CD8+高于对照组(P＜0.05)。两组患者治疗后LT、IL-4低于治疗前(P＜0.05),IFN-γ高于治疗前(P＜0.05)；研究组治疗后LT、IL-4低于对照组,IFN-γ高于对照组(P＜0.05)。研究组治疗总有效率(90.48%)高于对照组(71.43%)(P＜0.05)。多因素Logistic回归分析显示,基线FⅫa(OR=0.007,95% CI=0.000~0.338)、治疗方案(OR=4.530,95% CI=1.233~16.634)是慢性荨麻疹患者疗效的影响因素(均P＜0.05)。研究组总不良反应发生率对比对照组无明显统计学差异(P＞0.05)。结论:消风散+复方甘草酸苷片联合治疗慢性荨麻疹患者可有效改善症状,增强免疫功能,降低炎症反应,调节FⅫa、GATA-3表达水平,提高治疗效果,且不增加不良反应；同时发现慢性荨麻疹患者疗效受到基线FⅫa、治疗方案的影响。 |
| 英文摘要: |
| 【】 Objective? To explore the effect of Xiaofeng Powder combined with compound glycyrrhizin treatment on the levels of activated coagulation factor XII (FⅫa) and GATA conjunctiin-3 (GATA-3) in patients with chronic urticaria, and to further investigate the influencing factors of the therapeutic effect. Methods? A total of 84 patients with chronic urticaria who visited our hospital from June 2023 to June 2024 were selected and divided into a study group and a control group according to the random number table method, with 42 cases in each group. Patients in the control group were treated with oral administration of Compound glycyrrhizin Tablets, while those in the study group were treated with Xiaofeng Powder Decoction and oral administration of Compound glycyrrhizin Tablets. Both groups received 4 weeks of treatment. The symptom scores, immune functions (CD4+, CD8+, CD4+/CD8+), inflammatory factors [leukotrienes (LT), interleukin-4 (IL-4), interferon -γ(IFN-γ)], F xiia, GATA-3 before and after treatment were compared between the two groups. The effective rates of treatment in the two groups of patients were statistically analyzed, and Logistic regression was used to analyze the influencing factors of the therapeutic effect. Observe the incidence of adverse reactions. Results? After treatment, the expressions of FⅫa and GATA-3, symptom scores, and CD8+ in both groups were significantly lower than those before treatment (P<0.05), while CD4+ and CD4+/CD8+ were higher than those before treatment (P<0.05). After treatment, the expressions of FⅫa and GATA-3, symptom scores, and CD8+ in the study group were lower than those in the control group (P<0.05), while CD4+ and CD4+/CD8+ were higher than those in the control group (P<0.05). After treatment, LT and IL-4 in both groups of patients were lower than those before treatment (P<0.05), and IFN-γ was higher than that before treatment (P<0.05). After treatment, LT and IL-4 in the study group were lower than those in the control group, and IFN-γ was higher than that in the control group (P<0.05). The total effective rate of treatment in the study group (90.48%) was higher than that in the control group (71.43%) (P<0.05). Multivariate Logistic regression analysis showed that baseline FⅫa (OR=0.007, 95% CI=0.000-0.338) and treatment regimens (OR=4.530, 95% CI=1.233-16.634) were influencing factors for the therapeutic effect of patients with chronic urticaria (all P<0.05). There was no significant statistical difference in the total incidence of adverse reactions between the study group and the control group (P>0.05). Conclusion? The combined treatment of Xiaofeng Powder and Compound glycyrrhizin Tablets for patients with chronic urticaria can effectively improve symptoms, enhance immune function, reduce inflammatory response, regulate the expression levels of FⅫa and GATA-3, improve therapeutic effect, and does not increase adverse reactions. At the same time, it was found that the therapeutic effect of patients with chronic urticaria was affected by baseline FⅫa and the treatment plan. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
